Table 2.

Odds of a woman with an incident fragility fracture being on medical treatment for osteoporosis in year 1 vs subsequent years prospectively documented in women aged 50 and older in the Canadian Multicentre Osteoporosis Study

Year of CaMos study	Incident fracture rate n (%)	Any osteoporosis therapya		Bisphosphonate therapy		Hormone therapy
		OR	95%CI	OR	95%CI	OR	95%CI
2	128 (2.4)	1.15	0.66–2.00	1.69	0.90–3.2	0.82	0.45–1.52
3	107 (2.1)	0.95	0.53–1.73	1.74	0.88–3.42	0.60	0.35–1.04
4	94 (1.9)	1.42	0.77–2.61	2.72	1.31–5.62	0.68	0.33–1.41
5	125 (2.6)	1.09	0.64–1.84	1.90	0.97–3.70	0.60	0.32–1.11
6	104 (2.4)	1.21	0.70–2.10	2.25	1.19–4.27	0.76	0.43–1.35
7	90 (2.1)	1.51	0.85–2.69	3.57	1.79–7.15	0.27	0.10–0.72
8	94 (2.3)	1.67	0.94–2.98	3.94	1.99–7.80	0.28	0.11–0.70
9	112 (2.9)	1.50	0.88–2.55	4.14	2.21–7.74	0.15	0.06–0.36
10	104 (2.8)	1.16	0.65–2.07	3.65	1.83–7.26	0.07	0.02–0.24

^aHormone therapy, calcitonin, SERM, or bisphosphonate

^bOR controlled for BMD, age, smoking, and early menopause (younger than 45) status